RT Journal Article SR Electronic T1 ▾ Formestane for advanced breast cancer in postmenopausal women JF Drug and Therapeutics Bulletin JO Drug Ther Bull FD BMJ Publishing Group Ltd SP 85 OP 87 DO 10.1136/dtb.31.22.85 VO 31 IS 22 YR 1993 UL http://dtb.bmj.com/content/31/22/85.abstract AB Formestane (4-hydroxyandrostenedione) (Lentaron – Ciba) is the first of a new class of drugs that selectively inhibit aromatase, the enzyme that converts androgens to oestrogens. It is licensed for the treatment of postmenopausal women with advanced breast cancer and has been promoted by the manufacturer as offering new hope for those who have relapsed on tamoxifen.